Program of the 2017 Colloquium : Precision medicine and targeted therapies: realities and perspectives
Organised by :
Bernard DEVULDER, Dominique BELLET et Jean-Paul TILLEMENT
9:00 - 9:20
Introduction - Definitions & Objectives of the colloquium: Selective choices among relevant areas with established therapeutic progress
Pr. Dominique Bellet and Pr. Jean-Paul Tillement
The long-held practice of listening to, examining and treating individual patients is converging with genomic, bioinformatic and artificial intelligence technologies to create ‘precision’ medicine, which will transform the way we practise medicine. Learn about how these concepts are defined and what they mean for the future of clinical practice.
9:20 – 9:50
Incorporation of individual genetic and kinetic characteristics for pharmacological optimisation of drug therapies
Pierre MARQUET (Limoges)
Using the example of organ transplantation, P. Marquet describes how translational research may help to optimize therapeutic success, focusing on the genetic determinants of pharmacokinetics and the role of therapeutic drug monitoring.
9:50 – 10:20
Precision medicine - Standardised geriatric evaluation
Fati Nourhashémi (Toulouse)
Geriatric care will become increasingly important over coming decades as life expectancy increases. F. Nourhashemi describes how the standardized geriatric evaluation is changing to incorporate new understanding of the evolution and impact of frailty and trajectories of disability among elderly people.
10:20 – 10:50
Genomics and precision medicine: implementation and future prospects
Francis GALIBERT (Rennes)
Mapping of the human genome and the development of next generation sequencing (NGS) have led to advances in screening, pharmacogenetics and targeted therapies. Dr Galibert describes the impact of these advances on precision medicine, and the technological, regulatory, ethical and financial issues they have raised.
11:20 – 11:50
Taking drug-drug interactions into account: a monitoring platform
Jacques TURGEON (Moorestown, New Jersey)
Advances in bioinformatics have led to sophisticated clinical decision-making tools that can integrate data on a drug’s competitive inhibition, affinity, and metabolic pathways, and on a patient’s environmental and genetic factors. J. Turgeon shows us how these tools help to ensure patients receive individualised therapy with the greatest potential for benefit and the least potential for harm.
11:50 – 12:20
Therapeutic targeting of Interleukin 17: An example of translational medicine
Pierre MIOSSEC (Lyon)
14:00 – 14:30
Realities and future prospects of precision medicine. Type 2 diabetes and hypercholesterolaemia
André SCHEEN (Liège)
Type 2 diabetes and hypercholesterolemia both arise from a combination of genetic predisposition and environmental/lifestyle factors, but treatment practices for these conditions have taken a purely phenotypic approach. Learn how personalised medicine is being applied to treatment decisions in these two conditions, in order to individualise therapy and reduce the risk of cardiovascular morbidity and mortality.
14:30 – 15:00
Is tumor sequencing necessary for every cancer patient?
Christophe LE TOURNEAU (Paris)
Have we reached the stage where each cancer patient should have their tumour sequenced? C. Le Tourneau looks at whether cancer treatment can truly be individualised based on the patient’s tumoral genetic map, or whether we still have some way to go before universal tumour sequencing makes clinical sense.
15:00 – 15:30
Complex situations: the example of renal transplantation
Thierry HAUET (Poitiers)
More and more people are undergoing kidney transplant each year, but the success of these procedures is determined by a range of factors related to the donor, the host and the grafted organ. Although there are several scoring systems available to predict long-term graft outcomes, T. Hauet demonstrates how the application of precision medicine to graft evaluation has the potential to significantly improve transplant outcomes.
15:30 – 16:00
Gene Therapy: clinical achievements and future prospects
Salima HACEIN-BEY (Paris)
S. Hacein-Bey describes the history of gene therapy, the triumphs and failures of ex vivo gene transfer technology in hereditary diseases, the development of chimeric antigen receptor (CAR) T cell therapy for cancer, and the exciting opportunities that are emerging with new gene editing technologies such as CRISPR.
16:00 – 16:30
Thoughts about precision medicine: what is its scope? The reflections of an innocent on precision medicine
Jean-Pierre MICHEL (Genève)
JP. Michel asks what precision medicine means for clinicians and patients: what is its scope? What are the potential benefits and for whom? But also what are the potential challenges and risks for prescribers, patients, healthcare systems and regulators, and are we ready for the implications of this fundamental shift in medical practice?